|
Squamous cell carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
GAL, coding for the neuropeptide galanin, and GALR1, a galanin receptor, were identified as candidate genes of oncogenesis in SCC.
|
18973137 |
2009 |
|
Neuralgia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our previous research has shown that the expression of GalR1 is upregulated and that GalR1 activation in the nucleus accumbens (NAc) of rats with neuropathic pain has an antinociceptive effect.
|
31085289 |
2019 |
|
Neuralgia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These results suggested that GalR1 induced an antinociception via inhibiting PKA activation, implying that GalR agonists may be potential and potent therapeutic options to treat chronic neuropathic pain.
|
30904004 |
2019 |
|
Malignant Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
The receiver operating characteristics area under the curve, describing sensitivity and specificity to correctly identify the 41 women with both premalignant and malignant endometrial changes, was 0.93 (95% confidence interval, 0.87-0.97; P < 0.0001).GALR1 DNA methylation is one of the most common molecular alterations in endometrial cancer, and the presence of GALR1 methylation in vaginal swabs from women with postmenopausal bleeding indicates the presence of endometrial malignancy with a sensitivity of 92.7% and a specificity of 78.9%.
|
23727823 |
2013 |
|
Malignant neoplasm of endometrium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The receiver operating characteristics area under the curve, describing sensitivity and specificity to correctly identify the 41 women with both premalignant and malignant endometrial changes, was 0.93 (95% confidence interval, 0.87-0.97; P < 0.0001).GALR1 DNA methylation is one of the most common molecular alterations in endometrial cancer, and the presence of GALR1 methylation in vaginal swabs from women with postmenopausal bleeding indicates the presence of endometrial malignancy with a sensitivity of 92.7% and a specificity of 78.9%.
|
23727823 |
2013 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The results suggest that pharmacological agonists of GalR1-3 receptors can be a rational basis for drug developments in the field of cardiovascular diseases.
|
30551408 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we have identified a novel role for the GalR1/galanin receptor-ligand axis in chemoresistance, providing evidence to support its further evaluation as a potential therapeutic target and biomarker in CRC.
|
22859720 |
2012 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that endogenous galanin, acting through GalR1 may be involved in the pathophysiology of epilepsy-associated depression and ADHD via inhibiting RN-PFC serotonergic and LC-PFC noradrenergic transmissions respectively.
|
28013000 |
2017 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that endogenous galanin, acting through GalR1 may be involved in the pathophysiology of epilepsy-associated depression and ADHD via inhibiting RN-PFC serotonergic and LC-PFC noradrenergic transmissions respectively.
|
28013000 |
2017 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that endogenous galanin, acting through GalR1 may be involved in the pathophysiology of epilepsy-associated depression and ADHD via inhibiting RN-PFC serotonergic and LC-PFC noradrenergic transmissions respectively.
|
28013000 |
2017 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pharmacological analysis of tumor membrane homogenates with GAL and the specific GAL receptor GalR2 agonist, AR-M1896, revealed that the GAL receptor GalR1 is most likely the receptor responsible for the observed GAL binding in the glioblastomas.
|
12734662 |
2003 |
|
Heroin Dependence
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Fourteen SNPs showed nominally significant association with heroin addiction (p < 0.05), including the African-specific, missense SNP rs5376 (Asn334Ser) in the galanin receptor type 1 gene (GALR1) and the functional FKBP5 intronic SNP rs1360780.
|
24766650 |
2014 |
|
Hyperglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Potential clinical utility of galanin or peptidic analogs has been hindered by poor metabolic stability, lack of brain penetration, and hyperglycemia due to galanin receptor subtype 1 (GalR1) activation.
|
28098336 |
2017 |
|
Nicotine Dependence
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In support of our animal data, results from the association study show that variants in the GALR1 gene are associated with a protective effect in nicotine dependence (ND).
|
21796100 |
2011 |
|
Nicotine withdrawal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, using mouse models of nicotine reward and withdrawal, we show that there is a significant correlation between mecamylamine-precipitated nicotine withdrawal somatic signs and basal galanin or galanin receptor 1 (GALR1) expression in mesolimbocortical dopamine regions across the BXD battery of recombinant inbred mouse lines.
|
21796100 |
2011 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that the analyzed SNPs in GAL and GALR1 do not play a major role in early onset obesity or dietary fat intake in the obese children and adolescents of our study groups.
|
15930442 |
2005 |
|
Precancerous Conditions
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The receiver operating characteristics area under the curve, describing sensitivity and specificity to correctly identify the 41 women with both premalignant and malignant endometrial changes, was 0.93 (95% confidence interval, 0.87-0.97; P < 0.0001).GALR1 DNA methylation is one of the most common molecular alterations in endometrial cancer, and the presence of GALR1 methylation in vaginal swabs from women with postmenopausal bleeding indicates the presence of endometrial malignancy with a sensitivity of 92.7% and a specificity of 78.9%.
|
23727823 |
2013 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
NAX 810-2, a galanin receptor subtype 2 (GalR2)-preferring galanin analog, possesses 15-fold greater affinity for GalR2 over GalR1 and protects against seizures in the mouse 6 Hz, corneal kindling, and Frings audiogenic seizure models.
|
28098336 |
2017 |
|
Malignant neoplasm of mouth
|
0.010 |
Biomarker
|
group |
BEFREE |
Recently, GALR1 was also suggested as a tumor suppressor gene that was frequently silenced in head and neck squamous cell carcinoma; moreover, galanin and GALR1 were reported to inhibit human oral cancer cell proliferation.
|
29462183 |
2018 |
|
Lip and Oral Cavity Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recently, GALR1 was also suggested as a tumor suppressor gene that was frequently silenced in head and neck squamous cell carcinoma; moreover, galanin and GALR1 were reported to inhibit human oral cancer cell proliferation.
|
29462183 |
2018 |
|
Depression, Postpartum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of GALR1 in PFC Alleviates Depressive-Like Behaviors in Postpartum Depression Rat Model by Upregulating CREB-BNDF and 5-HT Levels.
|
30487761 |
2018 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest that endogenous galanin, acting through GalR1 may be involved in the pathophysiology of epilepsy-associated depression and ADHD via inhibiting RN-PFC serotonergic and LC-PFC noradrenergic transmissions respectively.
|
28013000 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
To the best of our knowledge, here, we reported for the first time the underlying mechanistic therapeutic efficacy of the ST against nonalcoholic fatty liver disease (NAFLD) in high-fat induced obese and galr1-deficient diabetic mice.
|
31843573 |
2020 |
|
Progressive pseudorheumatoid dysplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>HIGHLIGHTS</b> Expression level of GALR1 mRNA was significantly increased in PFC of estrogen withdraw-induced PPD rats.
|
30487761 |
2018 |
|
Neuropathy
|
0.010 |
AlteredExpression
|
group |
BEFREE |
These results illustrated that galanin induced antinociception in CeA in normal rats and rats with neuropathy, and there is an up-regulation of GalR1 expression in rats with neuropathy.
|
29127424 |
2017 |